We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

51 hedge funds and large institutions have $7.02M invested in Galectin Therapeutics in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less funds holding

Funds holding: 58 → 51 (-7)

23% less capital invested

Capital invested by funds: $9.08M → $7.02M (-$2.06M)

41% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 17

67% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 9

95% less call options, than puts

Call options by funds: $4K | Put options by funds: $85K

Holders
51
Holders Change
-7
Holders Change %
-12.07%
% of All Funds
1.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
10
Reduced
17
Closed
9
Calls
$4K
Puts
$85K
Net Calls
-$81K
Net Calls Change
+$136K

Top Buyers

Rank Fund Capital Flow
1
DADC
D.A. Davidson & Co
Montana
+$404K
2
AIG
American International Group
New York
+$104K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$36.3K
4
Creative Planning
Creative Planning
Kansas
+$18.4K
5
Millennium Management
Millennium Management
New York
+$14K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$560K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$434K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$384K
4
Northern Trust
Northern Trust
Illinois
-$278K
5
VKH
Virtu KCG Holdings
New York
-$124K
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
26
Rathbones Group
United Kingdom
$38K – – –
RBC
27
Ronald Blue & Co
Georgia
$37K – – –
VKH
28
Virtu KCG Holdings
New York
$35K -$124K -52,383 -78%
Morgan Stanley
29
Morgan Stanley
New York
$34K -$30.8K -13,056 -48%
State Street
30
State Street
Massachusetts
$28K – – –
New York State Common Retirement Fund
31
New York State Common Retirement Fund
New York
$24K -$25.3K -10,740 -51%
SWP
32
Stratos Wealth Partners
Ohio
$23K -$2.59K -1,100 -10%
Citadel Advisors
33
Citadel Advisors
Florida
$21K -$4.62K -1,957 -18%
GT
34
Glenmede Trust
Pennsylvania
$18K – – –
Creative Planning
35
Creative Planning
Kansas
$18K +$18.4K +7,817 New
WAM
36
Wolverine Asset Management
Illinois
$15K – – –
Wells Fargo
37
Wells Fargo
California
$11K -$6.45K -2,735 -38%
BIM
38
BlackRock Investment Management
Delaware
$7K – – –
UBS Group
39
UBS Group
Switzerland
$7K +$1.99K +845 +40%
Deutsche Bank
40
Deutsche Bank
Germany
$3K -$4.62K -1,958 -57%
First Manhattan
41
First Manhattan
New York
$3K – – –
LTFS
42
Ladenburg Thalmann Financial Services
Florida
$2K – – –
TRCT
43
Tower Research Capital (TRC)
New York
$1K -$1.03K -439 -57%
PNC Financial Services Group
44
PNC Financial Services Group
Pennsylvania
$1K – – –
TWA
45
TCI Wealth Advisors
Arizona
$1K – – –
SFM
46
Sphera Funds Management
Israel
– -$560K -205,000 Closed
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
– -$434K -183,931 Closed
D.E. Shaw & Co
48
D.E. Shaw & Co
New York
– -$384K -140,753 Closed
COPPSERS
49
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$93K -34,041 Closed
PP
50
Paloma Partners
Connecticut
– -$81K -29,850 Closed
1
2
3

GALT Hedge Fund Activity: Q3 2015 in Review

51 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2015, worth a combined $7.02M — down 23% from $9.08M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of GALT and 3 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 10 added.

The largest buyer was D.A. Davidson & Co, adding an estimated $404K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $560K sold.

  • 51 institutional investors held Galectin Therapeutics (GALT) as of Q3 2015, down from 58 in Q2 2015.
  • Funds reported $7.02M of Galectin Therapeutics stock for Q3 2015, down 23% quarter-over-quarter.
  • 3 funds opened new Galectin Therapeutics positions in Q3 2015 and 9 closed out, a net change of -6 holders.
  • The largest Galectin Therapeutics buyer in Q3 2015 was D.A. Davidson & Co, an estimated $404K added.
  • The largest Galectin Therapeutics seller in Q3 2015 was Sphera Funds Management, an estimated $560K sold.

Based on aggregated 13F filings for Q3 2015.